A strategic overview of the ten "good unknown unknown" compounds identified in Mānuka Performance's untargeted LC-HRMS honey screen — what they actually are, what it would take to convert them from a tentative mass-spec assignment into defensible IP, and how that process builds the broader bioactive intelligence moat described in the Four Pillar Strategy.
Out of 57,024 molecular features detected across 112 honey samples, 50,402 were deconvoluted into individual compounds, and 22,080 matched a library reference. The overwhelming majority of unmatched or low-confidence hits were noise or instrument artefacts. Ten compounds survived as "good" — present at reasonable abundance, across many samples, with clean enough spectra to support a tentative identification by accurate mass.
| Putative ID | Retention Time (min) | Ion Adduct | m/z | Chemical Class (inferred) |
|---|---|---|---|---|
| Bracteatin | 6.9 | [M-H]⁻ | 301.0354 | Aurone / flavonoid |
| Pseudosindorin | 7.9 | [M-H]⁻ | 271.0612 | Homoisoflavonoid |
| Isoliquiritigenin | 10.0 | [M-H]⁻ | 255.0663 | Chalcone |
| Pentahydroxydihydrochalcone | 4.2 | [M-H]⁻ | 289.0719 | Dihydrochalcone |
| Sulfuretin | 10.1 | [M-H]⁻ | 269.0456 | Aurone / flavonoid |
| Hispidol | 9.8 | [M-H]⁻ | 253.0506 | Aurone / flavonoid |
| Homobutein | 7.4 | [M-H]⁻ | 285.0769 | Chalcone |
| Isoliquiritigenin 4-methyl ether | 11.1 | [M-H]⁻ | 269.0819 | Chalcone (methylated) |
| Aurentiacin | 11.6 | [M+H]⁺ | 299.1278 | Flavonoid (uncertain) |
| Threo-L-3-[(2,4-dihydroxy-6-methylbenzoyl)oxy]-2-hydroxybutanoic acid | 2.3 | [M+H]⁺ | 271.0813 | Benzoate ester / organic acid |
Source: Analytica/ALS Final Report — Polyphenol Analysis of NZ Honeys, Table 3. Assignments are based purely on high-resolution accurate mass matched against a spectral library — no reference standard was run alongside any of these ten to confirm identity.
Before any IP conversation, it's worth being precise about what would and wouldn't actually be novel — because the patent law answer is different depending on which claim you're making, and conflating them wastes attorney time and weakens credibility with investors who ask follow-up questions.
Patenting is one tool among several. For natural-product chemistry at this early stage, the strongest near-term protection is often not a patent at all. Here's the realistic menu, ranked by how soon each is actually available to MPL.
The detection method, the specific honey/sample dataset, and the analytical parameters (chromatography conditions, m/z values, retention times under MPL's exact method) can be protected as trade secret immediately, at zero cost, simply by controlling access and using NDAs with any external party. This protects the "how we found it" even before "what we found" is confirmed. Cawthron's validated PolySure™ method is itself already functioning this way.
Once compounds are confirmed (Section 04), publishing a dated scientific paper or preprint establishes a priority claim and prior art — useful even where the molecule isn't patentable, because it stops a competitor from later claiming "first discovery in NZ honey" and prevents anyone else patenting a use you've already disclosed. This also generates PR and academic credibility (relevant to the Jinan University and Massey relationships already in motion).
Once a compound is confirmed and, ideally, linked to a specific bioactive function (antimicrobial, anti-inflammatory, antioxidant potency data), MPL can pursue a method-of-use patent ("use of compound X, isolated from NZ honey, for purpose Y") or a novel extraction/concentration process patent if the isolation method itself is inventive. These are narrower than a composition-of-matter patent but are realistic, defensible, and exactly the kind of asset the Waterfall Strategy's "pharma licensing pathway" depends on.
Trademark and certification-mark protection for PolySure™ itself, and for any future named compound profile (e.g. a branded "phytochemical signature" for a specific honey variety), is a separate and currently under-used lever. Brand-level IP doesn't require proving molecular novelty at all — it protects the commercial identity of the testing standard and the resulting certification, which is arguably the more immediately monetisable asset given where the science currently stands.
"Putative ID by accurate mass" is the lab's own caveat — the report explicitly notes these "may be some other isomer species." This is normal and expected at this stage of an untargeted screen; it is not a flaw in the work. What matters now is the next four steps, each of which is a concrete, fundable, schedulable piece of work.
The strategic value here isn't any single molecule — it's what the characterisation pipeline, repeated as a standing capability, does to MPL's competitive position over time.
Sequenced so each step is both individually fundable and a precondition for the next — consistent with the discovery → prioritisation → validation pattern that already worked for the seven PolySure™ polyphenols.
| Horizon | Action | Why / What It Unlocks |
|---|---|---|
| Now | Brief a patent attorney with chemistry/biotech and natural-products experience on this exact dataset (Table 3, plus this report) for an initial novelty and strategy assessment. | Cheapest, fastest way to get a real answer on what's patentable vs. what needs the publication/trade-secret route instead — should happen before spending on reference standards. |
| Now | Apply existing trade secret discipline (NDAs, access control) to the raw untargeted screening dataset and the specific analytical parameters behind these ten identifications. | Zero-cost protection available immediately, while confirmation work is still pending. |
| Now | File or extend trademark protection around PolySure™ and any named compound-profile branding likely to result from this work. | Brand-level IP doesn't depend on molecular novelty and is filing-ready today. |
| Near-term | Commission reference-standard confirmation (Step 1) for all ten compounds via Cawthron or Analytica, reusing the validated PolySure™ analytical infrastructure. | Converts "putative" to "confirmed" — the single highest-leverage technical step, and a precondition for every IP pathway except trade secret. |
| Near-term | Quantify confirmed compounds across the existing 112-sample set and map results against variety/geography/season metadata. | Determines which compounds are NZ/Mānuka-specific (strong provenance + IP story) vs. broadly distributed (weaker story) — directly informs which compounds are worth further investment. |
| Near-term | Prepare a defensive publication (peer-reviewed paper or preprint) on confirmed findings, ideally co-authored with an existing university partner (Massey, or the emerging Jinan relationship). | Establishes a dated priority claim and builds the same academic-credibility flywheel already working for the clinical trial programme. |
| Far-term | Commission bioactivity screening (Step 4) on the strongest NZ-specific candidates, and pursue use/process patent filings where data supports a specific functional claim. | The actual route to a defensible composition/use patent — only viable once confirmation and bioactivity data exist. |
| Far-term | Formalise the discovery → confirmation → quantification → bioactivity pipeline as a recurring annual cycle applied to each new season's untargeted screening data. | Turns a one-off finding into the standing capability that actually builds a compounding moat over multiple years, as described in Section 05. |